[go: up one dir, main page]

CR20220490A - Preparación de un compuesto que inhibe mcl-1 mediante metilación en presencia de agua - Google Patents

Preparación de un compuesto que inhibe mcl-1 mediante metilación en presencia de agua

Info

Publication number
CR20220490A
CR20220490A CR20220490A CR20220490A CR20220490A CR 20220490 A CR20220490 A CR 20220490A CR 20220490 A CR20220490 A CR 20220490A CR 20220490 A CR20220490 A CR 20220490A CR 20220490 A CR20220490 A CR 20220490A
Authority
CR
Costa Rica
Prior art keywords
methylation
mcl
preparation
water
inhibiting compound
Prior art date
Application number
CR20220490A
Other languages
English (en)
Inventor
Sheng Cui
Neil Fred Langille
Tsang-Lin Hwang
James E Huckle
Tian Wu
Markian Stec
Michal Achmatowicz
Janine K Tom
Sean P Brown
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20220490A publication Critical patent/CR20220490A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se describe un proceso mejorado para la síntesis del compuesto (A): <!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"> <v:stroke joinstyle="miter"/> <v:formulas> <v:f eqn="if lineDrawn pixelLineWidth 0"/> <v:f eqn="sum @0 1 0"/> <v:f eqn="sum 0 0 @1"/> <v:f eqn="prod @2 1 2"/> <v:f eqn="prod @3 21600 pixelWidth"/> <v:f eqn="prod @3 21600 pixelHeight"/> <v:f eqn="sum @0 0 1"/> <v:f eqn="prod @6 1 2"/> <v:f eqn="prod @7 21600 pixelWidth"/> <v:f eqn="sum @8 21600 0"/> <v:f eqn="prod @7 21600 pixelHeight"/> <v:f eqn="sum @10 21600 0"/> </v:formulas> <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/> <o:lock v:ext="edit" aspectratio="t"/></v:shapetype><v:shape id="Picture_x0020_18" o:spid="_x0000_i1025" type="#_x0000_t75" alt="" style='width:156pt;height:118.5pt'> <v:imagedata o:href="cid:image003.png@01D8D3F2.2D4D80F0"/></v:shape><![endif]-->(A), o una sal o solvato de este, mediante la metilación del compuesto (B):<!--[if gte vml 1]><v:shape id="Picture_x0020_17" o:spid="_x0000_i1026" type="#_x0000_t75" alt="" style='width:156pt; height:118.5pt'> <v:imagedata o:href="cid:image004.png@01D8D3F2.2D4D80F0"/></v:shape><![endif]-->(B), o una sal o solvato de este, un hidrato cristalino del compuesto A y formulaciones farmacéuticas que comprenden un hidrato cristalino del compuesto (A).
CR20220490A 2020-03-31 2021-03-30 Preparación de un compuesto que inhibe mcl-1 mediante metilación en presencia de agua CR20220490A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063002629P 2020-03-31 2020-03-31
US202063070630P 2020-08-26 2020-08-26
US202063084367P 2020-09-28 2020-09-28
PCT/US2021/024779 WO2021202452A1 (en) 2020-03-31 2021-03-30 Preparation of mcl-1 inhibiting compound by methylation in the presence of water

Publications (1)

Publication Number Publication Date
CR20220490A true CR20220490A (es) 2022-11-10

Family

ID=75581687

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220490A CR20220490A (es) 2020-03-31 2021-03-30 Preparación de un compuesto que inhibe mcl-1 mediante metilación en presencia de agua

Country Status (17)

Country Link
US (1) US20230117777A1 (es)
EP (1) EP4126883A1 (es)
JP (2) JP2021161114A (es)
KR (1) KR20220161368A (es)
CN (2) CN115397828A (es)
AU (2) AU2021246447B2 (es)
BR (1) BR112022019761A2 (es)
CA (1) CA3175912A1 (es)
CL (1) CL2022002665A1 (es)
CO (1) CO2022013968A2 (es)
CR (1) CR20220490A (es)
IL (1) IL296447A (es)
MX (1) MX2022012240A (es)
PE (1) PE20221907A1 (es)
TW (2) TW202140479A (es)
UY (1) UY39153A (es)
WO (1) WO2021202452A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102732008B1 (ko) 2018-05-14 2024-11-20 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
ES2995232T3 (en) 2019-11-26 2025-02-07 Gilead Sciences Inc Processes and intermediates for preparing mcl1 inhibitors
US12202782B2 (en) 2020-11-19 2025-01-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
AU2023215171A1 (en) * 2022-02-04 2024-07-04 Amgen Inc. Crystalline salt and solvate forms of murizatoclax (amg 397)
EP4472984A1 (en) * 2022-02-04 2024-12-11 Amgen Inc. Crystalline forms of an mcl-1 inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物

Also Published As

Publication number Publication date
PE20221907A1 (es) 2022-12-23
WO2021202452A1 (en) 2021-10-07
UY39153A (es) 2021-10-29
TW202140479A (zh) 2021-11-01
AU2021246447A1 (en) 2022-10-13
CO2022013968A2 (es) 2022-10-31
CN119080804A (zh) 2024-12-06
EP4126883A1 (en) 2023-02-08
CL2022002665A1 (es) 2023-06-09
AU2024200688A1 (en) 2024-02-22
IL296447A (en) 2022-11-01
TW202432554A (zh) 2024-08-16
JP2021161114A (ja) 2021-10-11
MX2022012240A (es) 2022-10-27
CA3175912A1 (en) 2021-10-07
BR112022019761A2 (pt) 2022-11-16
KR20220161368A (ko) 2022-12-06
JP2023519680A (ja) 2023-05-12
AU2021246447B2 (en) 2023-11-16
CN115397828A (zh) 2022-11-25
US20230117777A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
CR20220490A (es) Preparación de un compuesto que inhibe mcl-1 mediante metilación en presencia de agua
MX2021012756A (es) Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este.
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
MX2009001659A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12021552482A1 (en) Compounds targeting prmt5
MX2024000299A (es) Compuestos antivirales.
WO2013038429A3 (en) Novel sglt inhibitors
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
PH12021551873A1 (en) Hydroxypyridoxazepines as nrf2 activators
ZA202307945B (en) Pyridopyrimidinone derivative, preparation method therefor, and use thereof
MX2022012825A (es) Inhibidores de inmunoproteasoma.
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
PH12019501288A1 (en) Novel preparation containing benzimidazole derivative
NZ600107A (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
PH12021552953A1 (en) Tricyclic compounds
MX2019008436A (es) Inhibidores del inmunoproteasoma.
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
DE60215195D1 (de) Derivate morphinähnlicher opioidverbindungen
MX2021005681A (es) Combinacion de un inhibidor de mcl-1 y midostaurina, usos y composiciones farmaceuticas de la misma.
SA523440702B1 (ar) Ret مشتقات بيرازول كمثبطات كيناز